| |DECEMBER 20238Sanofi and Minapharm have announced the signing of an exclusive Manufacturing and Supply Agreement for the localization of the entire Clexane product line.The agreement between Sanofi, a global pharmaceutical company and Egypt's Minapharm, a regional Biotech company with wholly owned subsidiaries in Cairo and Berlin, boosts Egypt's national localization strategy of biopharmaceutical manufacturing. This move towards localizing the manufacturing of Sanofi's Clexane® adapts to changing market dynamics and enhancement of industrial innovative technologies, as per Minapharm.Clexane will be manufactured in Minapharm's second new state-of-the-art biopharmaceutical facility in Egypt, which is dedicated to the manufacturing, research, and development of complex bioengineered proteins.The agreement between the two companies was signed in the presence of Sanofi Senior Management, Christelle Saghbini, Head of Innovate to Grow Markets, Jeremy Goldnadel, Cluster Head International General Medicine, and Ahmed Youssef, Head of Manufacturing site, by Dr. Ahmed Raouf, Managing Director & Chairperson on behalf of Sanofi Egypt, and by Dr. Wafik Bardissi, Chairman and CEO of Minapharm on behalf of Minapharm.Dr. Ahmed Raouf, Managing Director and Chairperson of Sanofi Egypt said:" This agreement affirms Sanofi Egypt's pledge to support the localization plan of pharmaceutical and biological industries in Egypt by transfer of advanced manufacturing technology in cooperation with distinctive industry partners. This event comes as a continuation of efforts to provide essential and modern treatments to the Egyptian patient."POAs per Astellas Pharma US, Inc. Cresemba (isavuconazonium sulfate), an azole antifungal medication, has been approved by the US Food and medication Administration (FDA) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in paediatric patients.Cresemba for injection is approved for adults and now for paediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for paediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater. With this approval, Cresemba is now the only azole antifungal therapy approved for the treatment of IA and IM in patients as young as one, as per Pharmabiz."Invasive fungal infections are a significant concern to healthcare professionals who care for paediatric, adolescents and young adults with hematologic malignancies, transplant recipients and primary immune deficiencies," said Antonio C. Arrieta, M.D., medical director, Paediatric Infectious Disease, Children's Health of Orange County. "IA, currently the most common invasive mold infection in these patients, and IM are associated with significant morbidity and high fatality rates. The FDA approval of Cresemba for paediatric patients adds a much-needed treatment option.""The recent Covid-19 pandemic drove an uptick in these serious and life-threatening fungal infections, presenting an even greater urgency to address this growing unmet medical need," said Lynn Fenicchia, senior vice president and Head of US Medical Specialties Business Unit, Astellas. "Patients are waiting, and we know that young IA and IM patients are most at risk. Today's approval will bring hope to this highly vulnerable patient population with limited treatment options." POSANOFI & MINAPHARM INK PACT TO MANUFACTURE CLEXANEASTELLAS PHARMA BAGS US FDA NOD FOR CRESEMBA TO TREAT INVASIVE ASPERGILLOSISTOP STORIES
< Page 7 | Page 9 >